Olaparib (Lynparza) has now been approved by NICE as a second-line treatment of HER2-negative locally advanced or metastatic breast cancer in adults with mutated BRCA1 or BRCA2 genes who have had chemotherapy. Olaparib is a PARP inhibitor; PAPR is a protein which helps cancer cells repair themselves and Olaparib stops this repair process in these cases.
Secondary1st
Seeking a cure for secondary breast cancer
